By T N Ashok
NEW YORK: While families across America opened their January insurance statements to find premiums doubled overnight, governments from New Delhi to Brussels were doing something the United States Congress refused to consider: fighting back.
The contrast is damning. As 22 million Americans lost enhanced healthcare subsidies on January 1—triggering what policy analysts are calling the largest single transfer of wealth from the working poor to insurance companies in modern history—governments worldwide are waging an unprecedented war against pharmaceutical profiteering. The difference? In democracies from India to France, political survival depends on lowering drug costs. In Washington, it apparently depends on raising them.
The numbers are devastating in their simplicity. The average marketplace enrollee’s annual premium vaulted from $888 to $1,904—a 114% increase that arrived with the bureaucratic precision of a guillotine blade at midnight on New Year’s Eve. For a 60-year-old couple in Idaho earning $85,000, healthcare costs now devour nearly one-quarter of their take-home pay.
This is not a policy dispute. This is a mugging. “We’re watching the systematic dismantling of the last safety net between middle-class Americans and medical bankruptcy,” says Dr. Dana Goldman of the USC Schaeffer Institute. “And we’re doing it while every other developed nation—and many developing ones—are moving in the opposite direction.”
The Trump administration’s response? A photo opportunity with Pfizer and a website called TrumpRx.gov that offers discounts on drugs most Americans can’t afford to buy even at half price.
While Congress let the subsidies expire, India’s government was taking a drastically different approach to the same pharmaceutical giants.
In December, India’s National Pharmaceutical Pricing Authority slapped price caps on 800 essential medicines, including cancer treatments that American patients pay thousands for monthly. When Pfizer protested, the Modi government didn’t negotiate—it issued a compulsory license allowing Indian manufacturers to produce generic versions.
The political calculation is transparent: India faces national elections in 2029, and healthcare costs are the third-rail of Indian politics. A 2024 study found that 55 million Indians slip below the poverty line annually due to medical expenses. The government’s message to Big Pharma is unambiguous: accept regulated profits or we’ll eliminate your profits entirely.
“In India, letting people die because they can’t afford medicine is not a market solution—it’s a political death sentence,” explains Dr. Anant Bhan, a bioethics researcher in Bhopal. “Your Congress seems to have made the opposite calculation.”
The results speak volumes. The average Indian pays $1.50 for a month’s supply of the diabetes drug metformin. Americans pay $25. For the cancer drug imatinib, Indians pay $60 monthly. Americans pay $2,600.
If India wields the sledgehammer, Europe deploys the scalpel—with equal effectiveness. France’s Haute Autorité de Santé rejected Pfizer’s requested price for its COVID vaccine Comirnaty three times before agreeing to pay 40% of the U.S. rate. Germany’s Federal Institute for Drugs negotiates prices collectively for 83 million citizens. Britain’s National Health Service recently walked away from negotiations with Vertex Pharmaceuticals entirely, telling cystic fibrosis patients it would rather fund gene therapy research than pay “extortionate ransoms.”
The European model is brutal in its logic: pharmaceutical companies can either accept government-negotiated prices or abandon markets totaling 450 million consumers. Most take the deal.
Spain’s government went further. Last October, facing a close election, Prime Minister Pedro Sánchez announced a “Healthcare Shield” guaranteeing no family would pay more than 5% of income for insurance and medications combined. The program’s $8 billion annual cost? Funded by a windfall tax on pharmaceutical companies operating in Spain.
“American politicians talk about drug prices. European politicians regulate them,” says Professor Elias Mossialos of the London School of Economics. “The difference is we understand that healthcare costs win and lose elections. Your Republicans seem to have forgotten this.”
Perhaps most striking is China’s transformation into an unlikely champion of affordable medicine—not from altruism, but from the Communist Party’s obsession with social stability. In 2018, China launched its National Healthcare Security Administration with a mandate that would terrify American pharmaceutical executives: negotiate prices down by any means necessary, or face exclusion from the world’s largest healthcare market.
The results have been staggering. China negotiated a 95% price cut for the leukemia drug imatinib. It strong-armed AstraZeneca into accepting a 70% reduction for diabetes medications. When companies balked, China threatened to fast-track domestic generic production and suspend patent protections.
“The Party views healthcare costs as a direct threat to regime stability,” says Dr. Karen Eggleston of Stanford’s Asia Health Policy Program. “They’ve decided it’s cheaper to fight Pfizer than to fight protests. American politicians haven’t made that calculation yet—but November might change their minds.”
Against this global backdrop, the Trump administration’s “Most-Favored-Nation” deal with Pfizer appears less like diplomacy and more like performance art. The September Rose Garden ceremony promised “European prices for American patients.” The reality? Discounts on 15 drugs through a government portal that requires cash payment, while Pfizer simultaneously raised prices on 80 other medications—including a 15% increase for the very COVID vaccine the administration held up as proof of pharmaceutical partnership.
The voluntary discounts affect perhaps 100,000 Americans. The subsidy expiration devastates 22 million. “It’s genuinely insulting,” says Janet Weaver, a nurse in Boise whose premiums jumped $180 monthly. “India is threatening to nationalize drug production. France is taxing pharmaceutical profits. And we get a coupon website that doesn’t even work with insurance. It’s like offering someone a pamphlet on swimming techniques.”
The irony is savage: Republican leaders eliminated subsidies to reduce the deficit by $80 billion over ten years—roughly $230 per American annually. Meanwhile, families are paying an additional $1,000 in premiums immediately.
Even within the GOP, the political calculus is fracturing. Seventeen House Republicans from swing districts defected last week to vote for a three-year extension. Senate Majority Leader John Thune declared it “dead on arrival,” but his members from states like North Carolina and Arizona are receiving different messages from constituents.
“I spent thirty years telling voters that government healthcare is socialism,” admits Representative Tom Barrett of Michigan, who voted for the extension. “But when India’s capitalist government is capping drug prices and we’re not, what the hell am I supposed to call what we’re doing? Pro-business? It’s pro-bankruptcy.”
The fundamental question facing American voters in the midterms is not complicated: Why can the governments of India, China, and Europe protect their citizens from pharmaceutical profiteering, but the United States Congress cannot? The answer is equally simple: those governments fear their voters more than they fear their donors.
In India, healthcare costs toppled a state government in Karnataka last year. In France, Macron’s party surged after the Healthcare Shield announcement. In China, the Party’s survival depends on demonstrating it serves the people, not foreign corporations.
American politicians are about to discover whether the same logic applies here. “Every other democracy has figured out that letting people choose between medication and groceries is political suicide,” Dr. Goldman says. “Republicans are running an experiment to see if American exceptionalism extends to voters tolerating their own immiseration. I suspect they’re about to get their answer.”
For 22 million Americans, that answer can’t come soon enough. Their subsidies are gone. Their premiums have doubled. And their government is offering them discount coupons while the rest of the world declares war on the companies sending the bills.
The global healthcare crisis has revealed something uncomfortable: when it comes to protecting citizens from medical bankruptcy, Communist China is more responsive than democratic America. That’s not a talking point. That’s an indictment. And in November, it might just be a verdict. (IPA Service)
US Withdrawal From UN Agencies Offers A Good Opportunity To India 